Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 okt 2006 - 14:03
Statutaire naam
Crucell N.V.
Titel
Crucell Announces PER.C6® Commercial Licensing Agreement with ADImmune Corporation
Bericht
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a non-exclusive PER.C6® commercial license agreement with the Taiwan-based vaccine company ADImmune Corporation.
ADImmune intends to use the PER.C6® cell line technology to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China.
Datum laatste update: 01 september 2024